Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2
Basic Research in Cardiology · 24.07.2024 · 119 (5) · 751-772
DOI: 10.1007/s00395-024-01067-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Basic Research in Cardiology, online erschienen am 24.07.2024. Verfasst von Sha Chen und 21 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Experimental Intensive Care and Anesthesiology (L.E.I.C.A.), Department of Anesthesiology, Amsterdam Cardiovascular Sciences, Amsterdam…. Hauptthemen laut MEDLINE: Heart Failure, Sodium-Hydrogen Exchanger 1, Glucosides, Benzhydryl Compounds. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nemzeti Kutatási Fejlesztési és Innovációs Hivatal, Boehringer Ingelheim, European Foundation for the Study of Diabetes.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Sodium glucose cotransporter 2 inhibitors (SGLT2i) constitute the only medication class that consistently prevents or attenuates human heart failure (HF) independent of ejection fraction. We have suggested earlier that the protective mechanisms of the SGLT2i Empagliflozin (EMPA) are mediated through reductions in the sodium hydrogen exchanger 1 (NHE1)-nitric oxide (NO) pathway, independent of SGLT2. Here, we examined the role of SGLT2, NHE1 and NO in a murine TAC/DOCA model of HF. SGLT2 knockout mice only showed attenuated systolic dysfunction without having an effect on other signs of HF. EMPA protected against systolic and diastolic dysfunction, hypertrophy, fibrosis, increased Nppa/Nppb mRNA expression and lung/liver edema. In addition, EMPA prevented increases in oxidative stress, sodium calcium exchanger expression and calcium/calmodulin-dependent protein kinase II activation to an equal degree in WT and SGLT2 KO animals. In particular, while NHE1 activity was increased in isolated cardiomyocytes from untreated HF, EMPA treatment prevented this. Since SGLT2 is not required for the protective effects of EMPA, the pathway between NHE1 and NO was further explored in SGLT2 KO animals. In vivo treatment with the specific NHE1-inhibitor Cariporide mimicked the protection by EMPA, without additional protection by EMPA. On the other hand, in vivo inhibition of NOS with L-NAME deteriorated HF and prevented protection by EMPA. In conclusion, the data support that the beneficial effects of EMPA are mediated through the NHE1-NO pathway in TAC/DOCA-induced heart failure and not through SGLT2 inhibition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Experimental Intensive Care and Anesthesiology (L.E.I.C.A.), Department of Anesthesiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The…
- Dalton Cardiovascular Research Center, University of Missouri, Columbia, USA.
- Department of Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
- HUN-REN-SU System Pharmacology Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University, 1089, Budapest, Hungary.
- Pharmahungary Group, 6722, Szeged, Hungary.
- Department of Nutrition and Movement Sciences, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre+, Maastricht, The Netherlands.
ORCID-Profile: Coert J Zuurbier
Förderung
- Nemzeti Kutatási Fejlesztési és Innovációs Hivatal
- Boehringer Ingelheim
- European Foundation for the Study of Diabetes
Zitieren
APA
Chen, S., Wang, Q., Bakker, D., Hu, X., Zhang, L., van der Made, I., Tebbens, A. M., Kovácsházi, C., Giricz, Z., Brenner, G. B., Ferdinandy, P., Schaart, G., Gemmink, A., Hesselink, M. K. C., Rivaud, M. R., Pieper, M. P., Hollmann, M. W., Weber, N. C., Balligand, J. L., …, & Zuurbier, C. J. (2024). Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2. Basic Research in Cardiology, 119(5), 751-772. https://doi.org/10.1007/s00395-024-01067-9
Vancouver
Chen S, Wang Q, Bakker D, Hu X, Zhang L, van der Made I, et al. Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2. Basic Research in Cardiology. 2024;119(5):751-772. doi:10.1007/s00395-024-01067-9
BibTeX
@article{Chen2024,
author = {Chen, Sha and Wang, Qian and Bakker, Diane and Hu, Xin and Zhang, Liping and van der Made, Ingeborg and Tebbens, Anna M and Kovácsházi, Csenger and Giricz, Zoltán and Brenner, Gábor B and Ferdinandy, Peter and Schaart, Gert and Gemmink, Anne and Hesselink, Matthijs K C and Rivaud, Mathilde R and Pieper, Michael P and Hollmann, Markus W and Weber, Nina C and Balligand, Jean-Luc and Creemers, Esther E and Coronel, Ruben and Zuurbier, Coert J},
title = {Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2},
journal = {Basic Research in Cardiology},
year = {2024},
volume = {119},
number = {5},
pages = {751--772},
doi = {10.1007/s00395-024-01067-9}
}
EUVIMED